PDS0301 Updated Nov 11
PDS0301 is now PDS Biotech's sole internally-funded asset after the company discontinued its Phase 3 PDS0101 program in August 2026. The next catalyst is Q3 2026 earnings on November 12, 2026, where management may provide updates on the PDS0301 Phase 2 development plan and cash runway. Beyond that, watch for the company to outline a registrational path for PDS0301 in mCRC with liver metastases, which could involve an End-of-Phase 2 FDA meeting. The stock trades near $1.03 with a mean analyst target of $4.50, implying significant upside if the Phase 2 data translates into a viable registration strategy.
- Phase 2 data showed a 71% overall response rate (ORR) in metastatic colorectal cancer patients with liver metastases, a population with very poor prognosis and high unmet need.
- PDS0301 is a tumor-targeted immunocytokine (IL-12 antibody fusion) designed to concentrate IL-12 at the tumor site, potentially avoiding systemic toxicity while driving anti-tumor immunity.
- Dr. Patrick Soon-Shiong (NantWorks/Nant Capital) led a $22.3M PIPE financing in September 2026 and joined the Board, signaling deep-pocketed strategic support and potential access to NantWorks' infrastructure.
- PDS0301 is still in early-to-mid stage development (Phase 2), with no guarantee that the promising 71% ORR seen in small Phase 2 cohorts will replicate in larger, more rigorous trials.
- The company discontinued its Phase 3 PDS0101 program and laid off its pipeline to focus on PDS0301, making it a single-asset company with no revenue and high execution risk.
- PDSB stock crashed roughly 67% in August 2026 when the strategic refocus was announced, reflecting investor skepticism about abandoning a Phase 3 asset for a Phase 2 candidate.